It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we help you understand how your compound will behave in the body by assessing chemical and metabolic stability early in development. Our expertise accelerates optimization, improves pharmacokinetic predictions, and strengthens translational accuracy.
A compound’s chemical and metabolic profiling directly impact systemic exposure, therapeutic efficacy, and safety. Instability can lead to rapid clearance, shortened half-life, and compromised in vivo performance.
At Sygnature Discovery, we provide comprehensive in vitro chemical and metabolic stability assessments to support compound optimization and predict in vivo pharmacokinetics. Our assays evaluate parent depletion kinetics and intrinsic clearance (CLint) across species, enabling accurate IVIVE and guiding structure refinement. Importantly, our CLint data show strong correlation with in vivo CLint of marketed compounds, supporting successful scaling and enhancing translational confidence.
We offer targeted evaluations of:
Chemical Stability: Identifying pH-dependent degradation in biorelevant media
Plasma & Blood Stability: Assessing hydrolytic liability and ex vivo degradation risks
• Detects instability that can shorten half-life and reduce efficacy. • Prevents confounding pharmacokinetic data caused by ex vivo degradation. • Informs structural optimization for better performance.
• Assesses hydrolytic liability and enzymatic effects from plasma and red blood cells. • Addresses risks from esterases and amidases that influence degradation kinetics. • Ensures reliable pharmacokinetic measurements.
• Captures Phase I and Phase II metabolism in intact liver cells. • Provides species-specific data for accurate predictions. • Supports modeling of systemic exposure, half-life, and dosing strategies.
• Quantifies transporter-mediated clearance to resolve IVIVE disconnects. • Improves prediction accuracy for compounds with active transport components. • Validated in human and rat hepatocytes for translational confidence.
Bifunctional degraders bind and degrade proteins via ubiquitin ligase, despite breaking bRo5 rules. Translating in vitro DMPK data to in vivo performance remains a challenge. At Sygnature Discovery, we provide tailored assays and expertise to support projects involving these compounds. Read more in the poster.
Learn from Dr Phillip MacFaul, Sygnature Discovery’s Principal Scientist in DMPK about measuring EPSA in bifunctional degraders.
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
